Maintains Buy
Thursday, August 1, 2019
Amicus up 2% premarket on positive data on Batten disease gene therapy
Amicus Therapeutics (NASDAQ:FOLD) perks up 2% premarket on light volume in response to encouraging preliminary data from a Phase 1/2 clinical trial evaluating its AAV-CLN6 gene therapy in patients with a rare inherited nervous system disorder called CLN6 Batten disease.
Interim data from the first eight children receiving a one-time intrathecal (into the spinal canal) administration of AAV-CLN6 showed a disease stabilization rate of 88% (n=7/8) up to two years after treatment.
The safety profile was favorable with most adverse events being mild.
Myriad Genetics up 27% on new insurance coverage for GeneSight test
Myriad Genetics (MYGN +27.1%) is up on light volume in early trade in response to a positive coverage decision at UnitedHealthcare for pharmacogenetic testing with multigene panels, including MYGN’s GeneSight Psychotropic test, for patients with major depressive disorder who have failed at least one prior line of therapy.
Argenx SE reports 1H results
Argenx SE (NASDAQ:ARGX): 1H net loss of €45.1M
Revenue of €43.53M (+143.0% Y/Y)
Subscribe to:
Posts (Atom)